Gaucher disease: clinical profile and therapeutic developments

References

• FuchsVRNew priorities for future biomedical innovationsN Engl J Med2010363870470620818873
   PubMed Web of Science ®Google Scholar
• BradyROKanferJNShapiroDMetabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s diseaseBiochem Biophys Res Commun19651822122514282020
   PubMed Web of Science ®Google Scholar
• BeutlerEGrabowskiGAGaucher diseaseScriverCRBeaudetALSlyWSValleDThe Metabolic and Molecular Basis of Inherited DiseaseIII8th edNew York, NYMcGraw-Hill200136353668
   Google Scholar
• ReczekDSchwakeMSchröderJLIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidaseCell2007131477078318022370
   PubMed Web of Science ®Google Scholar
• BalreiraAGasparPCaiolaDA nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndromeHum Mol Genet200817142238224318424452
   PubMed Web of Science ®Google Scholar
• BerkovicSFDibbensLMOshlackAArray-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosisAm J Hum Genet200882367368418308289
   PubMed Web of Science ®Google Scholar
• ZimranAKayAGelbartTGaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patientsMedicine (Baltimore)19927163373531435229
   PubMed Web of Science ®Google Scholar
• CoxTMSchofieldJPGaucher’s disease: clinical features and natural historyBaillieres Clin Haematol19971046576899497857
   PubMed Web of Science ®Google Scholar
• EriksonAGaucher disease – Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatmentActa Paediatr Scand Suppl1986326S1S42
   PubMedGoogle Scholar
• BultronGKacenaKPearsonDThe risk of Parkinson’s disease in type 1 Gaucher diseaseJ Inherit Metab Dis201033216717320177787
   PubMed Web of Science ®Google Scholar
• MeiklePJHopwoodJJClagueAECareyWFPrevalence of lysosomal storage disordersJAMA199928132492549918480
   PubMed Web of Science ®Google Scholar
• BeutlerENguyenNJHennebergerMWGaucher disease: gene frequencies in the Ashkenazi Jewish populationAm J Hum Genet199352185888434610
   PubMed Web of Science ®Google Scholar
• CoxTMGaucher disease: understanding the molecular pathogenesis of sphingolipidosesJ Inherit Metab Dis200124Suppl 210612111758671
   PubMed Web of Science ®Google Scholar
• AertsJMHollakCEPlasma and metabolic abnormalities in Gaucher’s diseaseBaillieres Clin Haematol19971046917099497858
   PubMed Web of Science ®Google Scholar
• MoranMTSchofieldJPHaymanARShuGPYoungECoxTMPathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin KBlood20009651969197810961902
   PubMed Web of Science ®Google Scholar
• JmoudiakMFutermanAHGaucher disease: pathological mechanisms and modern managementBr J Haematol2005129217818815813845
   PubMed Web of Science ®Google Scholar
• NilssonOSvennerholmLAccumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher diseaseJ Neurochem19823937097187097276
   PubMed Web of Science ®Google Scholar
• PelledDTrajkovic-BodennecSLloyd-EvansESidranskyESchiffmannRFutermanAHEnhanced calcium release in the acute neuronopathic form of Gaucher diseaseNeurobiol Dis2005181838815649698
   PubMed Web of Science ®Google Scholar
• FutermanAHvan MeerGThe cell biology of lysosomal storage disordersNat Rev Mol Cell Biol20045755456515232573
   PubMed Web of Science ®Google Scholar
• ImD-SHeiseCENguyenTO’DowdBFLynchKRIdentification of a molecular target of psychosine and its role in globoid cell formationJ Cell Biol20011532420434
   Web of Science ®Google Scholar
• CoxTMAertsJMBelmatougNManagement of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringJ Inherit Metab Dis200831331933618509745
   PubMed Web of Science ®Google Scholar
• DeeganPBPavlovaEVTindallJOsseous manifestations of adult Gaucher disease in the era of enzyme replacement therapyMedicine (Baltimore)2011901In press.
   Web of Science ®Google Scholar
• HobbsJRJonesKHShawPJLindsayIHancockMBeneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher’s syndromeLancet198718542111111152883444
   PubMed Web of Science ®Google Scholar
• RingdenOGrothCGEriksonAGranqvistSMånssonJESparrelidETen years’ experience of bone marrow transplantation for Gaucher diseaseTransplantation19955968648707701581
   PubMed Web of Science ®Google Scholar
• HoogerbruggePMBrouwerOFBordigoniPAllogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow TransplantationLancet19953458962139814027760610
   PubMed Web of Science ®Google Scholar
• AshwellGMorellAGThe role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteinsAdv Enzymol Relat Areas Mol Biol197441991284609051
   PubMedGoogle Scholar
• StahlPDRodmanJSMillerMJSchlesingerPHEvidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophagesProc Natl Acad Sci U S A197875313991403274729
   PubMed Web of Science ®Google Scholar
• BradyROEnzyme replacement for lysosomal diseasesAnn Rev Med20065728329616409150
   PubMed Web of Science ®Google Scholar
• FurbishFSSteerCJKrettNLBarrangerJAUptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylationBiochim Biophys Acta198167344254346784774
   PubMed Web of Science ®Google Scholar
• BartonNWFurbishFSMurrayGJGarfieldMBradyROTherapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher diseaseProc Natl Acad Sci U S A1990875191319162308952
   PubMed Web of Science ®Google Scholar
• BartonNWBradyRODambrosiaJMReplacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher’s diseaseN Engl J Med199132421146414702023606
   PubMed Web of Science ®Google Scholar
• GrabowskiGABartonNWPastoresGEnzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sourcesAnn Intern Med1995122133397985893
   PubMed Web of Science ®Google Scholar
• WeinrebNJCharrowJAnderssonHCEffectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registryAm J Med2002113211211912133749
   PubMed Web of Science ®Google Scholar
• AnderssonHKaplanPKacenaKYeeJEight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1Pediatrics200812261182119019047232
   PubMed Web of Science ®Google Scholar
• SimsKBPastoresGMWeinrebNJImprovement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort studyClin Genet200873543044018312448
   PubMed Web of Science ®Google Scholar
• OnoHFujiwaraMItoKUedaHMizoguchiNSakuraNNeurological features in Gaucher’s disease during enzyme replacement therapyActa Paediatr200190222923111236058
   PubMed Web of Science ®Google Scholar
• EriksonAForsbergHNilssonMAströmMMånssonJETen years’ experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher diseaseActa Paediatr200695331231716497642
   PubMed Web of Science ®Google Scholar
• WeinrebNTaylorJCoxTYeeJvom DahlSA benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imigluceraseAm J Hematol2008831289089518819093
   PubMed Web of Science ®Google Scholar
• ZimranAAltarescuGPhilipsMPhase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experienceBlood2010115234651465620299511
   PubMed Web of Science ®Google Scholar
• ShaaltielYBartfeldDHashmueliSProduction of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell systemPlant Biotechnol J20075557959017524049
   PubMed Web of Science ®Google Scholar
• AviezerDBrill-AlmonEShaaltielYA plant-derived recombinant human glucocerebrosidase enzyme – a preclinical and phase I investigationPLoS One200943e4792 Epub 2009 Mar 11.19277123
   PubMed Web of Science ®Google Scholar
• PastoresGMWeinrebWJAertsHTherapeutic goals in the treatment of Gaucher diseaseSemin Hematol2004414 Suppl 541415468045
   PubMed Web of Science ®Google Scholar
• SchiffmannRHeyesMPAertsJMProspective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s diseaseAnn Neurol19974246136219382473
   PubMed Web of Science ®Google Scholar
• DaviesEHEriksonACollin-HistedTMengelETylki-SzymanskaAVellodiAOutcome of type III Gaucher disease on enzyme replacement therapy: review of 55 casesJ Inherit Metab Dis200730693594217994286
   PubMed Web of Science ®Google Scholar
• EriksonARemaining problems in the management of patients with Gaucher diseaseJ Inherit Metab Dis200124Suppl 2122126 discussion 87–88.11758672
   PubMed Web of Science ®Google Scholar
• VunnanRRRadinNSAnalogs of ceramide that inhibit glucocerebroside synthetase in mouse brainChem Phys Lipids19802632652786445239
   PubMed Web of Science ®Google Scholar
• RadinNSTreatment of Gaucher disease with an enzyme inhibitorGlycoconj J19961321531578737239
   PubMed Web of Science ®Google Scholar
• EndoAA gift from nature: the birth of the statinsNat Med200814101050105218841147
   PubMed Web of Science ®Google Scholar
• InokuchiJRadinNSPreparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetaseJ Lipid Res19872855655712955067
   PubMed Web of Science ®Google Scholar
• AbeARadinNSShaymanJAStructural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growthJ Lipid Res19953636116217775872
   PubMed Web of Science ®Google Scholar
• PlattFMNeisesGRDwekRAButtersTN-butyldeoxnojirimycin is a novel inhibitor of glycolipid biosynthesisJ Biol Chem199426911836283658132559
   PubMed Web of Science ®Google Scholar
• ButtersTDvan den BroekLAGMFleetGWJMolecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesisTetrahedron Asymmetry2000111113124
   Web of Science ®Google Scholar
• PlattFMNeisesGRReinkensmeierGPrevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycinScience199727653114284319103204
   PubMed Web of Science ®Google Scholar
• JeyakumarMButtersTDCortina-BorjaMDelayed symptom onset and increased life expectancy in Sandhoff mice treated with N-butyldeoxynojirimycinProc Natl Acad Sci U S A199996116388639310339597
   PubMed Web of Science ®Google Scholar
• CoxTLachmannRHollakCNovel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisLancet200035592141481148510801168
   PubMed Web of Science ®Google Scholar
• ElsteinDHollakCAertsJMSustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher diseaseJ Inherit Metab Dis200427675776615505381
   PubMed Web of Science ®Google Scholar
• HeitnerRElsteinDAertsJWeelySZimranALow-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher diseaseBlood Cells Mol Dis200228212713312064906
   PubMed Web of Science ®Google Scholar
• PastoresGMBarnettNLKolodnyEHAn open-label, noncomparative study of miglustat in type 1 Gaucher disease: efficacy and tolerability over 24 months of treatmentClin Ther20052781215122716199246
   PubMed Web of Science ®Google Scholar
• CoxTMAertsJMAndriaGThe role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. Advisory Council to the European Working Group on Gaucher DiseaseJ Inherit Metab Dis200326651352614605497
   PubMed Web of Science ®Google Scholar
• GiraldoPAlfonsoPAtutxaKReal-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL projectHaematologica200994121771177519608672
   PubMed Web of Science ®Google Scholar
• van der SpoelACJeyakumarMButtersTDReversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraceptionProc Natl Acad Sci U S A20029926171731717812477936
   PubMed Web of Science ®Google Scholar
• SuganumaRWaldenCMButtersTDAlkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformitiesBiol Reprod200572480581315576825
   PubMed Web of Science ®Google Scholar
• WeinrebNJBarrangerJACharrowJGrabowskiGAMankinHJMistryPGuidance on the use of miglustat for treating patients with type 1 Gaucher diseaseAm J Hematol200580322322916247743
   PubMed Web of Science ®Google Scholar
• SchiffmannRFitzgibbonEJHarrisCRandomized, controlled trial of miglustat in Gaucher’s disease type 3Ann Neurol200864551452219067373
   PubMed Web of Science ®Google Scholar
• WraithJEVecchioDJacklinEMiglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trialMol Genet Metab201099435135720045366
   PubMed Web of Science ®Google Scholar
• LeeLAbeAShaymanJAImproved inhibitors of glucosylceramide synthaseJ Biol Chem199927421146621466910329660
   PubMed Web of Science ®Google Scholar
• McEachernKAFungJKomarnitskySA specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseMol Genet Metab200791325926717509920
   PubMed Web of Science ®Google Scholar
• HirthBHSiegelCSynthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors. United States patent US 68558302005215
   Google Scholar
• MarshallJMcEachernKAChuangWLImproved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapyJ Inherit Metab Dis201033328128920336375
   PubMed Web of Science ®Google Scholar
• PeterschmittMJBurkeABlanksteinLSafety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteersJ Clin Pharmacol In press 2010. MS Reference: JCP-09-Nov-437.R1.
   Google Scholar
• LukinaEWatmanNArreguinEAA phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1Blood2010116689389920439622
   PubMed Web of Science ®Google Scholar
• LukinaEWatmanNAvila ArreguinEImprovement in hematological, visceral and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz 112638) treatment: two-year results of a phase 2 studyBlood2010816 [Epub ahead of print]
   Web of Science ®Google Scholar
• ParentiGTreating lysosomal storage diseases with pharmacological chaperones: from concept to clinicsEMBO Mol Med20091526827920049730
   PubMed Web of Science ®Google Scholar
• CartierNHacein-Bey-AbinaSBartholomaeCCHematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophyScience2009326595481882319892975
   PubMed Web of Science ®Google Scholar
• MigitaMMedinJAPawliukRSelection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectorsProc Natl Acad Sci U S A1995922612075120798618847
   PubMed Web of Science ®Google Scholar
• EnquistIBNilssonEOokaAEffective cell and gene therapy in a murine model of Gaucher diseaseProc Natl Acad Sci U S A200610337138191382416954197
   PubMed Web of Science ®Google Scholar
• EnquistIBNilssonEMånssonJEEhingerMRichterJKarlssonSSuccessful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher diseaseStem Cells200927374475219056909
   PubMed Web of Science ®Google Scholar
• McEachernKANietupskiJBChuangWLAAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher diseaseJ Gene Med20068671972916528760
   PubMed Web of Science ®Google Scholar
• HighKAThe Jeremiah Metzger lecture: gene therapy for inherited disorders: from Christmas disease to Leber’s amaurosisTrans Am Clin Climatol Assoc200912033135919768188
   PubMedGoogle Scholar
• HollakCEvom DahlSAertsJMForce majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher diseaseBlood Cells Mol Dis2010441414719804996
   PubMed Web of Science ®Google Scholar
• RoosJCHyryHICoxTMOrphan drug pricing my warrant a competition law investigationBr Med J2010341c64711084108621081598
   PubMed Web of Science ®Google Scholar